Tempus AI, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Tempus AI, Inc. - overview
Established
2015
Location
Chicago, IL-Illinois, US
Primary Industry
Healthcare IT
About
Tempus AI, Inc. is a US-based company specializing in AI-driven precision medicine solutions that enhance patient care through advanced data analysis and technology integration. Founded in 2015 and headquartered in Chicago, US, Tempus AI, Inc. focuses on precision medicine by combining data analytics with clinical insights.
Eric Lefkofsky is the founder and CEO at Tempus. Tempus has established a strong presence in the healthcare sector, utilizing innovative strategies to adapt to market needs. In May 2026, Tempus AI, Inc. raised USD 400 million in venture debt financing.
Tempus offers a comprehensive suite of AI-enabled precision medicine solutions that improve patient care through sophisticated data analysis. Their primary offerings include genomic profiling, algorithmic tests, and advanced software that aids healthcare providers in making informed treatment decisions. Notable products like Tempus Hub and Tempus One support oncologists and healthcare systems by facilitating data integration and personalized treatment matching. Additionally, Tempus enhances clinical trial matching with digital pathology solutions, helping pharmaceutical partners leverage real-world data in drug development.
For the year 2025, Tempus reported revenue of USD 1271. 70 mn, accompanied by an EBITDA of USD 119. 52 mn. The company's revenue model is built on subscriptions and partnerships with healthcare providers, enabling them to utilize their extensive range of services under tailored contracts.
In May 2026, Tempus AI plans to use the funding primarily to repay existing debt and reduce interest costs, improving its balance sheet and financial flexibility.
Current Investors
New Enterprise Associates, Revolution Ventures, T Rowe Price
Primary Industry
Healthcare IT
Sub Industries
Healthcare IT, Oncology/Cancer Treatment, Mental Health Services, Dermatology, Medical Software
Website
www.tempus.com
Verticals
Artificial Intelligence, Artificial Intelligence, HealthTech, Mobile Apps
Company Stage
Mature
Total Amount Raised
Subscriber access only
Tempus AI, Inc. - timeline of key events
Tempus AI, Inc. - financials
| Fiscal Year Ended | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|
| Revenue (USD) | 320,668,000 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - |
| EBITDA (USD) | (229,935,000) | - | - | - |
| Operating Income (USD) | (265,442,000) | - | - | - |
| Operating Margin | (82.8%) | - | - | - |
| % EBITDA Margin | (71.7%) | - | - | - |
| NET Income (USD) | (289,811,000) | - | - | - |
| % Net Margin | (90.4%) | - | - | - |
Tempus AI, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Announced | Personalis, Inc. | - | ||||||||
| Venture Debt | Completed | Tempus AI, Inc. | - | ||||||||
| Add-on, Trade Sale | Completed | Paige, Inc. | - | ||||||||
| Venture Debt | Announced | Tempus AI, Inc. | - | ||||||||
| Add-on, Trade Sale | Completed | Deep 6 AI Inc. | - |
Displaying 1 - 5 of 24
Tempus AI, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.